Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update
This Competitive Intelligence report about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar recombinant monoclonal antibodies in comparison with the corresponding originator antibodies and biosuperior antibodies against the same target. The report also describes the next wave of potential biosimilar versions of therapeutic antibodies loosing patent protection in the time frame of 2019 – 2023. The report specifically lists for each target the branded products with their 2015 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.
Browse Market info, get a Sample PDF with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=724046
The report includes a compilation of marketed, approved and currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets relevant for the first wave of biosimilar antibodies (VEGF, TNF, Her2, CD20, EGF-R). Relevant first wave originator therapeutic antibodies are Humira, Enbrel, Remicade, Avastin, Lucentis, Eylea, Herceptin, Rituxan/MabThera and Erbitux. Second generation therapeutic antibodies against these targets such as Symponi, Cimzia, Cyramza, Perjeta, Arrzera are also subject of biosimilar activities.
The report also addresses the slowly emerging second wave of biosimilar antibody activities against originator therapeutic antibodies such as abatacept, alemtuzumab, denosumab, eculizumab, omalizumab, pavilizumab, tocilizumab, and ustekinumab.
Click to submit Query/ Enquiry: http://www.researchmoz.us/enquiry.php?type=E&repid=724046
Table of Content
A) 2015 SALES OF THERAPEUTIC ANTIBODIES
Overview: 2015 Biologics Sales per Class of Products
Overview: 2015 Therapeutic Antibody Sales per Class of Products
Blockbuster Therapeutic Antibodies in 2015
Anti-TNF Antibody Sales in 2015
Cancer Antibody Sales in 2015
Other Anti-Inflammatory Antibody Sales in 2015
Ophthalmic Antibody Sales in 2015
Cardiometabolic & Anti-Infective Antibody Sales in 2015
B) BIOSIMILAR AND BIOSUPERIOR ANTI-TNF ANTIBODIES – 2016 UPDATE
1. Originator Anti-TNF Antibodies
Approved and Marketed Indications of anti-TNF Antibodies in Regulated Markets
2015 SALES OF ANTI-TNF ANTIBODIES
Sales of Anti-TNF Antibodies in Q1/2016
Humira Pipeline of Recently Approved Indications & Upside Developments
Remicade Pipeline of Recent Approvals & Upside Indications
Enbrel Pipeline of Upside Indications
Simponi Pipeline of Recent Approvals & Upside Indications
Cimzia Pipeline of Recent Approvals & Upside Indications
Defense Strategies against Biosimilar Anti-TNF Antibodies
2. Biosuperior Anti-TNF Antibodies
Non-Antibody Anti-TNF Biosuperiors
Anti-TNF Biosuperior Antibodies
3. Biosimimilar Anti-TNF Antibodies
Humira Biosimilar Antibodies:
Developments in Regulated Markets
Developments in Less Regulated Markets
Enbrel Biosimilar Antibodies:
Developments in Regulated Markets
Developments in Less Regulated Markets
Remicade Biosimilar Antibodies:
Developments in Regulated Markets
Developments in Less Regulated Market
Simponi & Cimzia Biosimilar Antibodies
About ResearchMoz
ResearchMoz is the worlds fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMozs service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG